Lilly Stock - Search News

Eli Lilly Stock Rises

Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before

Seeking Alpha · 1d

Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and pricing challenges loom. See more here.

Wall Street Journal · 1d

Eli Lilly Stock Rises After Earnings Beat Forecasts

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes drug Mounjaro rose in the fourth quarter.

Weight Loss Drug Demand Drives Eli Lilly Sales

Reuters · 1d

Lilly reassures investors that weight-loss drug demand is strong, shares rise

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Business Insider · 1d

Eli Lilly (NYSE:LLY) Speeds Up Weight Loss Drug Data Release

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s leader can become

The Financial Times · 1d

Eli Lilly expects to beat profit forecasts on obesity drug demand

The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to sharp sell-offs in its shares.

1don MSN

Why Eli Lilly Stock Popped on Thursday

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

1don MSN

Eli Lilly’s Disappointing Quarter Was Already Baked In

Eli Lilly ripped off the bandage when it reported preliminary fourth-quarter results in mid-January, getting the bad news out ...

Eli Lilly Up 13.3% in 2025: Stock Soars as New Breakthroughs Set to Fuel Explosive Growth

Eli Lilly is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are exp ...

1don MSN

Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly Stock Rises After Earnings Beat, Upbeat Guidance

Eli Lilly stock rose after the drugmaker posted quarterly earnings that beat Wall Street expectations, and issued upbeat 2025 guidance. Fourth-quarter adjusted earnings came in at $5.32 a share, above ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Eli Lilly Stock Rises

Weight Loss Drug Demand Drives Eli Lilly Sales

Related topics